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Abstract
In the development of innovative technology products, companies of all sizes are being
encouraged to innovate responsibly and regulators are encouraged to adapt their regu-
latory systems to be smarter, more proportionate and adaptive to the needs of innovative
technologies. The British Standards Institution Responsible Innovation (RI) Guide
(Publicly Available Specification [PAS] 440) is an industry‐wide standard relevant to both
these policy trends. It supports companies by providing a framework to demonstrate the
balance between the potential benefits and harms and, if necessary, to take action to
maximise the benefits and/or minimise the harms. It includes guidance on engagement
with stakeholders and will codify what stakeholders can expect from companies under-
taking responsible innovation, paving the way to more harmonious relationships among
stakeholders with differing interests and values. A cross‐sectoral survey of innovative
companies showed that 90% favoured the development of such a standard. PAS 440 was
also trialled in two early‐stage biotechnology companies and its expected benefits
included contributing to coordinated responsible behaviour along a supply chain; better
company and stakeholder understanding of the product properties; supporting decision‐
making on whether or not to start a company; considering the risks of not developing the
product and avoiding reputational risks. Benefits were expected to be increasingly sig-
nificant as the RI standard becomes widely adopted.
1 | INTRODUCTION
The innovation ecosystem for products of engineering biology
is complex and rapidly evolving and companies face a daunting
array of challenges in guiding their products to market. As in all
other sectors of the economy, they will need to find a viable,
resilient and adaptive business model and a place for their
product in an existing supply chain or in some cases devise a
new business model and even a new supply chain serving a
new market.
Additionally, regulatory systems can be more time‐
consuming and expensive than for many other sectors,
creating significant barriers to entry for innovative small com-
panies, particularly those lacking capital or resource and devel-
oping transformational products that would be disruptive of the
business models of the current companies [1]. Many of today's
regulatory systems are based on those introduced in the 20th
century for technologies that are very different from innovative
biotechnologies, and innovators are nevertheless expected to
adapt their innovations to meet the needs of these regulatory
systems [2]. However, a new ethos is emerging whereby regu-
lators are increasingly willing to adapt their regulatory systems to
help society benefit safely from innovative technologies [3] as
has been the case with the recent regulatory fast tracking of
vaccines against COVID‐19, based on synthetic biology. Future
regulatory systems across the board are expected to be more
proportionate and adaptive to the risks and benefits of new
technologies. They will be smarter and more targeted, rather
than involving a lowering of standards for safety, quality and
efficacy, and standards are expected to play a major role in the
future regulatory reform [2]. Regulators are increasingly inter-
ested in exploring better ways to ensure public safety is main-
tained while not delaying beneficial innovation and have
received government support for such initiatives [4].
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In accordance with this regulatory reform agenda, since
pre‐2000s, there have been calls for more ‘responsible’ research
and innovation (RRI) [5], supported by generous research
funding schemes, particularly the EU's Horizon 2020 pro-
gramme. Most of the projects funded by these initiatives have
focused on responsible research (RR) rather than responsible
innovation (RI) and until very recently, there has been a lack of
guidance for companies on how they are expected to innovate
responsibly [6].
These parallel initiatives, regulatory reform and RI, are not
independent. An important aspect of RI is the need for
companies to engage with public stakeholders and citizens to
ensure that their needs and desires are being taken into ac-
count in the innovation process, and ensuring that innovative
technologies will be effectively regulated is a recurring theme
in most engagement initiatives. Successful regulatory reform
will therefore need to go hand in hand with a greater focus
from companies on demonstrating that they are innovating
responsibly.
This article makes the case for a standard to support
companies in delivering RI and in demonstrating that they have
done so, and describes the development and application of the
British Standards Institution (BSI) Responsible Innovation
Guide, PAS 440 [7], also referred to here as the RI standard. A
Publicly Available Specification (PAS) is a type of BSI standard
that is commissioned by an external sponsor and developed
rapidly to respond to an immediate business need. A ‘Guide’
gives less prescriptive advice than some other forms of stan-
dard and reflects the current thinking and practice amongst
experts in a subject.
We describe the experience of trialling the RI standard on
two cases involving small companies at the start of their
innovation journey, and draw some conclusions relevant to its
future development.
2 | BUILDING A CASE FOR A
RESPONSIBLE INNOVATION STANDARD
Compared to responsible research, different issues will arise at
later developmental stages for a product, and different actors
and stakeholders will be involved. Also, decisions will need to
be made on timescales that reflect the real challenges faced by
companies in a competitive economic environment. The
Technology Strategy Board (TSB, now Innovate UK), in 2012,
was the first UK funding body to apply RI principles to
companies applying for public funding for translational
research projects in synthetic biology [8]. The TSB Responsible
Innovation Framework (RIF) aimed ‘… to fund projects where
the ‘anticipated commercial use’ of the project outcomes
meets, on the balance of positive and negative drivers, the
standards outlined … for responsible innovation’; and ‘… to
help companies anticipate and give responsible
consideration to the intended and potential unin-
tended impacts of the commercial development and use of
the technology, including the potential for misuse, before the
work begins’ (TSB emphases).
The TSB's RIF reflected the organisation's role as a public
sector funder, and was based on (i) positive drivers (factors in
favour of supporting projects), (ii) negative drivers (factors
against supporting projects) and (iii) regulatory drivers. In PAS
440, the perspective shifts to that of the innovating company.
However, further development of this approach to RI
standard development hit a roadblock at about this time. It was
initially applied only to those working on synthetic biology‐
related innovation and companies were understandably con-
cerned that theirs should not be the only sector required to
demonstrate that it was innovating responsibly. Other inno-
vation programmes run by the TSB/Innovate UK at that time
invested in areas where the societal implications were better
understood, and there was felt to be no need to deploy the RIF
in such areas. Agreement among companies on the need for a
standard is an essential prerequisite for its development.
In the intervening years, pressure for companies to
demonstrate responsible innovation has increased and become
more pervasive influenced, among other things, by evidence of
questionable data use by some data analytics companies [9] and
by questions being raised about breakthrough technologies like
facial recognition, other uses of AI, robotics and driverless
vehicles.
The 2017 PAGIT report [2] recommended the develop-
ment of an RI standard in the context of regulatory reform,
and this coincided with a more general company understanding
of the value of being able to demonstrate that they are inno-
vating responsibly, for example [7, p. iv]:
� long‐term cost and risk reductions;
� more resilient new product/service offerings to potential
customers;
� improvement of societal trust in the company and mainte-
nance of social licence to operate;
� improved relations with investors and greater investor
confidence in the company;
� greater attractiveness as an employer;
� better supply chain relationships;
� improved reputation and brand value;
� increased innovation capabilities;
� improved ability to communicate the value of products and
services to investors, companies, customers and citizens;
� better relationships with governments, regulators and local
communities; and
� improved capacity for long‐term planning and sustainability.
3 | DEVELOPING PAS 440
3.1 | Scoping survey to assess demand
The first stage in the development of PAS 440 was a survey,
conducted through BSI, of companies that were potential users
of such a standard. This was a critical point for the project. If
there was no enthusiasm for it, it would have been harder to
justify going ahead. The aim of the survey was to assess the
appetite in industry to use an RI standard; provide an
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indication of what ‘responsible innovation’ would mean to the
companies; gain insight on what it should cover; and explore
any differences between the innovation areas.
Considerable thought was given to selecting whom to
interview, to learn the perspectives of businesses of different
sizes, operating in a range of technology and market areas. The
in‐depth interview‐based survey involved 48 companies in the
following sectors: AI and big data, 13; life sciences, 7; robotics
and autonomous systems, 7; social media, 7; advanced mate-
rials, 7; and others, 7. There was good representation of both
companies operating a business‐to‐business model and of
those with a business‐to‐consumer model. Forty‐three com-
panies (90%) considered the development of the RI standard
to be quite important or very important.
At the same time as this survey, Doteveryone undertook a
similar questionnaire‐based survey of 1010 technology pro-
fessionals that included a question from BSI/Innovate UK:
‘How interested are you in the idea of a single framework for
the responsible governance of innovation, that lays out the
basic principles to be considered, and that could be used by
companies of all size for any technology in any market?’ On
answering this question, 78% of respondents were either very
interested or fairly interested.
Quotes from the companies involved in this survey pro-
vided guidance on how they would like to see the RI standard
developed, covering the following areas:
� the current lack of a framework to help companies to ‘… do
the right things for the right reasons’;
� encouraging companies to think about what could go
wrong;
� countering current trends towards public misinformation;
� acting as a checklist of key issues with a practical, rather than
a theoretical focus;
� encouraging companies to think about the public good as-
pects of their innovations;
� it should be as dynamic, flexible and adaptable as the
technologies it embraces;
� companies should be able to demonstrate compliance, that
is, it should be an accreditable standard; and
� it should be broad enough to cover all potential use cases
but specific enough to be useful.
There was also a positive response to the involvement of
Innovate UK in the development of the RI standard, including
that it ‘is the most natural standard‐bearer for this framework’,
is ‘setting the innovation agenda in the UK’ and ‘sends the
right signals to those working with innovative technologies’.
Most of the minority negative opinions expressed by
companies in the survey related to the potential risk that a
poorly designed PAS might become overly burdensome and
stifle innovation. As these companies emphasised, it should be
an enabler, not a barrier to innovation, it should be easy to
implement and not the ‘… place where some innovation goes
to die’, and it should not exacerbate the UK's current risk
aversion where we will ‘… occupy the moral high ground but
go bust in the process’.
The challenge for those developing the PAS was thus to
deliver a framework that supports companies in behaving
responsibly, enables them to communicate widely that they are
behaving responsibly and at the same time adds value to their
business, and is manageable within the resource constraints of
operating in fiercely competitive environments.
3.2 | Delivering on expectations
Insights gained from earlier research, particularly the PAGIT
report funded by BEIS/BSI [10], had already identified many
of the issues raised during the PAS 440 survey and had led to
proposals for developing an RI approach that is proportionate
to the needs of companies developing innovative technologies.
The original TSB RIF took a similar approach in 2012, so the
approach is well recognised and widely supported.
The following features, building on the TSB work, refined
during the PAGIT project and consolidated in PAS 440, are
intended to ensure that the RI process is manageable, even for
small companies, by being proportionate to the needs and
properties of the innovative technologies involved, their stage
of development and the likely extent of stakeholder interest.
The RI standard has the potential to codify what members of
the public can reasonably expect from companies when they
advocate responsible innovation and hence pave the way to
more harmonious relationships between stakeholders with
differing interests and values. As explained in the preface to
PAS 440 [7, p ii], 440 Hz is ‘concert pitch’, the frequency of the
note to which the whole orchestra tunes to ensure that they
play in harmony. The RI standard will perform a similar
function so that innovation delivering new products, services
and processes will work for all parts of a supply chain, and be
accepted by wider society.
PAS 440, as a practical guide, is particularly targeted to
transformative (disruptive) innovations across a broad range of
business sectors, including life sciences. It attempts to be
realistic about the demands on company resources (time and
money) in often fiercely competitive environments. It also
aims to support companies in understanding what is needed
to deliver RI at different stages in the development process,
for different types of innovation across all developmental
stages up to and beyond the market launch and gives guid-
ance on charting a path through the potentially conflicting
aspirations and demands of a broad range of different
stakeholders.
Several important features set this RI standard apart from
other approaches to RI.
1. It sets out basic principles to support company decision‐
making, particularly where there are multiple stakeholder
interests and values. A clear distinction is made between
principles that are relevant to the behaviour of the company
as a whole (e.g. respect for international norms of behaviour
and for human rights), and principles that are relevant to
the development of specific innovations. Innovation‐
specific principles include the EU Precautionary Principle
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which is relevant to situations where there is uncertainty
about future benefits and risks of an innovation [11] and the
EU Innovation Principle [12, 13], intended as a comple-
mentary, balancing principle to the Precautionary Principle,
recognising the need to protect society and the environment
while also safeguarding a nation's ability to innovate. The
underlying principles of proportionality and adaptation are
applied to regulations and policies, designed to ensure that
protecting society from potential harm should, where
possible, avoid stifling beneficial innovation. RI is expected
to strike a balance across these principles.
2. It recognises that RI should be different at different stages
of the innovation process and for different types of inno-
vation (incremental innovation where the RI process can be
a more ‘light touch’, and transformative innovation where
stakeholder interests and values may be more contentious
and the RI process more demanding) [1].
3. It takes on board the relative capacities of large and small
companies to undertake RI and sets out clearly what can
be expected from smaller companies with limited
resources.
4. Recognising the need for a company to demonstrate publicly
that it is behaving responsibly, it provides a framework to do
so that is easily understood by companies of any size and
their stakeholders. This builds on procedures that are already
familiar to many companies, such as compliance with a social
responsibility standard and using a risk assessment matrix as
part of conventional project management.
5. It explicitly incorporates the need to be aware of and to
comply with other existing regulations and standards.
6. Stakeholder engagement is an important part of RI,
particularly for transformative innovations and any others
that are potentially contentious, and guidance is also pro-
vided on how to conduct engagement initiatives.
PAS 440 involves an iterative process that revisits a com-
pany's RI monitoring at intervals appropriate to the speed of
development of the innovation and takes account of any
substantive changes in its properties or plans for future market
targeting.
4 | APPLICATION CASE STUDIES
This section describes two case studies carried out as disser-
tation projects by Masters students at Strathclyde University
(A. Brown, Industrial Biotechnology Innovation Centre
Collaborative Masters in Industrial Biotechnology) and the
University of Edinburgh (I. Cabrera Lalinde, Masters in
Management of the Bioeconomy, Innovation and Gover-
nance). Both involved spin‐out companies using synthetic
biology‐related technologies to develop products for future
markets. Both Masters projects were short (approximately
3 months) and so the extent of implementation of PAS 440
was limited. The case studies provided evidence to support the
companies in further implementing PAS 440 and making it an
integral part of their future development processes.
4.1 | Case study 1—MiAlgae
In developing an understanding of MiAlgae's perspective on the
PAS 440 framework, its impact on the company and its inno-
vation plans, semi‐structured interviews were carried out with
representatives of the organisation and of their key stake-
holders, including the aquaculture industry, the whisky industry
and not‐for‐profit organisations providing financial support.
4.1.1 | RI standard‐related challenges in this field
MiAlgae is a small industrial biotechnology company that is
currently at a critical scale‐up stage, having recently received
significant investment for the development of their product, an
omega‐3‐rich algae‐based oil. The main market for MiAlgae's
product is the aquaculture industry where it is required to meet
the consumer standards for omega‐3 levels in farmed salmon
and other carnivorous fish species. It is produced from co‐
products of the whisky industry and would supplement the
current supply of omega‐3 oils from wild‐caught fish, poten-
tially having a significant impact on the environmental sus-
tainability of the sector.
The public visibility of these consumer‐focused sectors
requires careful consideration of any new product introduction
or collaborative project [14]. This emphasises the importance
of conducting innovation responsibly and the potential value
of a widely recognised RI framework.
4.1.2 | Applying PAS 440—MiAlgae and
stakeholder perspectives
MiAlgae saw itself as working to improve the sustainability of
the aquaculture industry and noted that there is a risk, if they
do not develop their product, of continued reliance on wild
fish as a source of omega‐3 oils. They also saw themselves as
making a contribution to a circular bio‐economy. The company
has adopted the ISO 14001 Environmental Standard and en-
sures that its business partners are operating to ethical re-
sponsibility requirements, but they do not yet have any
formalised goals in the RI area.
MiAlgae foresaw a potential reputational risk at the time of
a future product launch, requiring a stronger focus on being
able to demonstrate their sustainable practices to external
stakeholders. Although PAS 440 is seen as having the potential
to improve their reputation, brand value and overall stake-
holder relationships, they could only justify the time spent on it
if it had a definitive, measurable benefit for the organisation.
Some important customers in the aquaculture industry were
more interested in product price than sustainability, but many of
the companies wanting to collaborate with MiAlgae are also
looking for sustainable solutions and have already addressed
such issues. They have identified a future improvement by
including sustainability criteria in their tendering process to
ensure that their partners comply with the same general stan-
dards to which MiAlgae operates.
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Exploring MiAlgae's current RI‐related initiatives and its
relationships with stakeholders provided a baseline to build
responsible innovation, based on PAS 440, into its own stan-
dard operating procedures and disseminating this along the
supply chain in future.
Stakeholders commented on how MiAlgae's adoption of
PAS 440 could have a positive impact on their own relationship
with the company and with the wider industry. All agreed that
adoption of the PAS 440 framework would deliver for MiAlgae
all the benefits proposed above in Section 2, particularly based
on its value as a tool to communicate with non‐technical
stakeholders, such as supermarkets. It could usefully summa-
rise much of the key information sought by these stakeholders.
Like MiAlgae, stakeholders also considered that the full
value of the framework would only be realised once it had
gained a wider recognition, given that it is only in the early
stages of implementation. They thought that it would be
particularly useful as a starting point for developing an
approach to RI for smaller organisations with limited resources
to fulfil its requirements. However, stakeholders also saw it as
challenging to convince these organisations to commit the
necessary resources when they cannot see it as directly relevant
to the growth of their company.
Stakeholders involved in funding also noted that com-
panies taking the time to plan their RI approach at an early
stage in the product development would be able to avoid delays
later on when applying for financial support by pre‐identifying
potential benefits and hazards linked to their product intro-
duction and if necessary suggesting mitigations.
4.1.3 | PAS 440 viability and opportunities for
improvement
An important recommendation from the dissertation was that
translational bodies such as the Industrial Biotechnology
Innovation Centre (IBioIC) could champion the framework to
assist small companies with limited resources to adopt PAS 440
as a standard. Such organisations already have strong re-
lationships with innovative companies in their sector and could
promote the framework more widely with a significant impact
on awareness and its adoption.
4.2 | Case study 2—Norfolk Plant Sciences
Norfolk Plant Sciences (NPS) is commercialising a purple to-
mato product, containing enhanced levels of anthocyanins, to
be sold in the form of juice. It is a spin‐out company from the
John Innes Centre (JIC) and The Sainsbury Laboratory (TSL),
both independent research institutes specialising in plant and
microbial science and genetics. Among many other claimed
benefits, anthocyanins can reduce the incidence of cancer and
improve cardiovascular function [15,16] and regulatory
approval for the product is being sought from the US Food
and Drug Administration and Department of Agriculture. PAS
440 was viewed in this case study as a means to support JIC
decision‐making on the creation of spinout companies for the
commercialisation of its research, raising awareness of the
social, ethical and regulatory challenges.
Interviewees included representatives of JIC and TSL who
have been particularly involved in commercialising this tech-
nology, along with others from organisations used by JIC in
supporting commercialisation of its research.
4.2.1 | RI standard‐related challenges in this field
Much of the research on plant science and agricultural
biotechnology has focused on overcoming human chronic,
non‐communicable diseases while also contributing to more
sustainable and productive agricultural practices. Targeting
phytonutrients such as anthocyanins can help to counteract the
effects of poor or restricted diets in developed and developing
countries.
Claims that the use of genetic technologies can improve
both productivity and human health have been faced with
citizen concerns about associated hazards, and the commer-
cialisation of such products is potentially sensitive to public
perception. Widespread misinformation about the products of
genetic technologies have also influenced the expected
marketability of new developments [17].
Adoption of plant genetic technologies to overcome soci-
etal and environmental challenges is accompanied by demands
for more transparency, encouraging companies to make extra
efforts to deal with uncertainties that might threaten their
position in the market. Here PAS 440 provides a bridge to a
better understanding of the balance between positive contri-
butions and potential hazards from an innovation, significantly
influencing how new products entering the market will be
perceived.
4.2.2 | Applying PAS 440—NPS and JIC
perspectives
Based on the PAS 440 RIF template, the aims of the project
were to guide NPS and JIC to identify positive and negative
elements related to this innovation, to provide insights on how
to address any issues arising at different stages in the devel-
opment process, and to document the outcomes of their RI
approach. The work aimed to suggest areas where RI practices
can contribute to advanced understanding of the relationships
between companies and stakeholders relevant to positive or
negative societal or environmental impacts.
Considering organisation‐level responsibility, JIC has an
excellent history of engagement in RR on which to build RI,
and interviewees recognised the importance of RI in moving to
a more sustainable future for NPS. JIC has ensured that its
commitment to diversity, equality and inclusion, and its vision
to address global challenges through plant science, remain at
centre stage as the product is commercialised. JIC interviewees
agreed that many of the corporate‐level requirements for RI
are already in place, but that some might not be simple to
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implement, for example, where the behaviour of potential
partners in the future supply chain of a product is concerned.
The proposed RI model could raise questions within JIC, NPS
and its technology transfer company, on the economic and
social value of the product, and there were also some concerns
about JIC losing power over future development decisions
made by NPS.
Considering product‐specific elements relevant to the
purple tomato, given the involvement of innovative genetic
technologies in the development of this product, it may attract
negative attention from citizens and public interest activist
groups. The case study used the PAS 440 RIF to categorise
these elements, record the reasons for their inclusion and
identify relevant stakeholders, and actions to be taken, to
provide reassurance. The following positive outcomes of the
innovation were identified: promoting the availability of
affordable and nutritious food; educating local children; stim-
ulating local businesses in developing countries; supporting
sustainable production and consumption patterns; limiting
cultivation to contained‐environment agriculture to remove the
risks from genetic spread via pollination in open agriculture;
and protecting communities against a range of non‐
communicable diseases. Potential negative outcomes and is-
sues included public and advocacy group concerns about
innovative biotechnologies; the need for further assessment of
the toxicology of the compounds present in the tomatoes;
potential reputational damage from association with other
companies in the supply chain and monitoring responsible
behaviour of partners; and the need to assess the future
environmental impact.
4.2.3 | PAS 440 viability and opportunities for
improvement
Companies that proactively implement a framework to inno-
vate responsibly could be better prepared for the challenges of
a rapidly changing innovation ecosystem. An important benefit
of implementing the RI standard was seen to be acquiring the
ability to cope with and anticipate innovation‐related issues,
including establishing protocols to move from a focus on RR
to RI.
The flexibility and adaptability of PAS 440 will simplify the
process of integrating different perspectives, given that it can
be adapted to a changing environment, and can be used to
align corporate and societal behaviours. Implementation of the
RI standard prompted debates on changes that would have to
be made within JIC to facilitate the creation of spinout com-
panies and to cope with stakeholder demands in a competitive
environment. In such cases, RI has a role to play in pitching to
investors, for example, a seed fund to support the translation
of JIC's innovation in agri‐food and health.
PAS 440 was also seen to have potential benefits to JIC and
stakeholders by fostering wider recognition of the RI standard
throughout the biotechnology industry sector.
PAS 440 could improve communication between stake-
holders involved in the creation of spinout companies and
guide the distribution of resources to facilitate commerciali-
sation. Embedding responsible business practices within the
corporate culture can translate into economic benefits resulting
from reducing technical barriers to commercialisation of the
innovation. It can also minimise costs arising from unforeseen
circumstances related to stakeholder engagement and effi-
ciency along the supply chain.
5 | CONCLUSIONS AND NEXT STEPS
5.1 | Conclusions relevant to the case studies
The two case studies presented here contribute to a body of
knowledge on the usefulness of the PAS 440 Guide, what
works and what should be changed or added to in future. Both
case studies involved small companies, but MiAlgae had
already received significant private investment, and was further
along the commercialisation journey than NPS. NPS senior
staff were still employed by their parent research institutes,
giving them a different perspective on the future development
process; also, the intended market for the purple tomato as a
food for human consumption will create additional regulatory
hurdles that will not apply to MiAlgae's omega‐3 oil and will
take longer to negotiate, slowing down translation to a market.
Even though work had only recently begun, both com-
panies could already see benefits in the adoption of PAS 440,
and these were expected to become more significant as it
became more widely adopted, creating greater future incentives
for companies to adopt the RI standard. Despite these benefits,
both MiAlgae and NPS foresaw some future hazards arising
from association with other companies that might bring
reputational damage or that did not appreciate the value of RI
given their strong focus on getting a rapid return on their in-
vestment, the latter factor leading to concerns about the time
and staff investment needed to deliver RI.
Given some of the companies' hesitancies, particularly
those due to lack of resources, there was a greater willingness
in both companies to implement the RI standard on a product‐
by‐product basis, rather than to commit to adopting it across
the board at this stage. The staged approach recommended by
PAS 440 leaves space to allow a company to decide at what
point to begin to consider RI. There might be some value in
waiting until it is clear that a product has commercial potential
before formally adopting an RI initiative. However, taking this
on at an earlier stage would reduce or remove some of the
uncertainty arising from investing in a product before evalu-
ating RI‐related issues.
Here, as in most RI initiatives, stakeholder engagement
was an important theme. It was seen as a two‐way process,
allowing stakeholders to express their interests and expecta-
tions relevant to a product, and the company to have a role in
framing stakeholder understanding of the product and its
benefits and hazards. Particularly in the early stages of the
product development, interaction with a broad range of
stakeholders can enable a company to identify new markets for
a product, or potential future problems that might arise in later
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stages. However, across all relevant stakeholders, there may
not be a consensus on all the issues discussed. Each stake-
holder will have a different perspective on the adoption and
value of an innovation and the RI process can reassure
stakeholders that all aspects of the innovation are being
carefully considered.
Historically, stakeholder engagement has provided oppor-
tunities for some activist groups to exert a disproportionate
influence on the public framing of innovative technologies and
PAS 440 includes guidelines on engagement with stakeholders,
taking on board the principle of equity and the onus on all
parties involved in an engagement initiative to behave equally
responsibly [7, p. 19].
5.2 | The uptake and future development of
PAS 440
In general, technology is neither good nor bad; it is how it is
used that matters. Electricity lights and heats our homes, but an
electric shock can kill. Medicines can cure ill health, but most
are also poisonous. Pressure has been building over the past 10
years for the introduction of an RI standard that takes account
of the joint needs of companies and their stakeholders and PAS
440 has an important role to play as an industry‐wide standard.
It aims to support companies of all sizes to do the right thing
by providing a framework to demonstrate the balance between
potential benefits and harms and, if necessary, highlights ac-
tions to maximise the benefits and/or minimise the harms.
Adoption of PAS 440 could improve communication between
partners and stakeholders involved in the creation of spinout
companies and guide the distribution of resources to facilitate
commercialisation.
The PAS process enables a guide to be rapidly developed in
order to fulfil an immediate need in industry, and PAS 440 has
had an enthusiastic reception from companies across many
innovative sectors of the economy. On the day of its launch in
April 2020, it was downloaded from the BSI website more than
a thousand times, a record for any BSI standard. At the time of
writing in December 2020, it had reached 2700 downloads,
more than the total for all the BSI standards supported by
Innovate UK [18].
A series of webinars undertaken by BSI and the Knowl-
edge Transfer Network in 2020, to support the cohort of the
Innovate UK Fast Start COVID‐19 competition, introduced
participants to PAS 440 and they considered it very digestible.
Many participants had not engaged before with BSI and the RI
Guide provided a practical support where the impact aligned
well with the innovator's intentions. BSI informal discussions
with major multinational companies have noted that they use
similar processes to PAS 440 to assess responsibility and that
the Guide would also be very useful to them. PAS 440 thus
resonates with many companies already familiar with standards
and is also an easy first step into understanding and using
standards for those who are unfamiliar with them.
Two insights emerged from the case studies that should be
considered for incorporation in future versions of the RI
standard. First, it could be used to support decision‐making on
whether or not to start a company, for example, providing
information on the supply chain and stakeholder alignment
and gaps in understanding but, as noted in Section 3, it should
also avoid leading to a reputation for RI as ‘… the place where
some innovation goes to die’. Second, the concept of inte-
grating RI application along a supply chain, rather than
applying it piecemeal to individual companies, could give that
supply chain an advantage over competitors.
Taking up the points in Section 4 about the lack of re-
sources for small companies to engage fully with PAS 440,
accelerators could play a role as champions, providing early‐
stage finance and mentoring. Similarly, IBioIC and other
publicly funded translational bodies could provide a supportive
environment for the adoption of the RI standard.
If many companies are actively using PAS 440, that could
pave the way for further future developments as an accredi-
table British Standard, or a constituent part of the UK input
into the development of a European or International Standard.
5.3 | Links between innovation, regulatory
reform and responsible innovation
As noted in the introduction, we are experiencing simultaneous
expansion in the scale and speed of innovation across many
sectors of the economy alongside recognition of the need for
our regulatory systems to be more proportionate and adaptive
to the properties of innovative technologies. As these trends
continue, it will be increasingly essential for companies to
demonstrate that they support, and are implementing a
responsible approach to innovation and the availability of PAS
440 is already making a major contribution to this process.
Other societal trends are moving in a similar direction to dis-
cussions on RI, for example, challenging traditional economic
models and introducing a role for alternative value categories
[19]. PAS 440 could be among the first of a series of standard
tools to support better integration of values between industry
and citizens.
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